以岭药业 (002603.SZ) Latest Company News

Aug 31, 2026, 23:17 UTC
China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 28, 2026, 09:37 UTC
Yiling Pharmaceutical announced its first-half 2026 results with revenue of 4.075 billion yuan, net profit of 757 million yuan, and no dividend distribution.
Source:
- finance.sina.cn
Aug 12, 2026, 08:55 UTC
Yiling Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of its self-developed Class 1 chemical new drug LB220-D08 sustained-release tablets, a complement inhibitor targeting Factor B for atypical hemolytic uremic syndrome.
Source:
- finance.sina.cn
Jul 16, 2026, 04:14 UTC
Shijiazhuang Yiling Pharmaceutical (02005.HK) obtained a drug production registration approval from the National Medical Products Administration for fenofibrate choline sustained-release capsules, classified as Category 4 chemical drugs and deemed to have passed consistency evaluation.
Source:
- aastocks.com
- aastocks.com
Jul 10, 2026, 09:05 UTC
Shijiazhuang Yiling Pharmaceutical (02005) received drug production registration approvals from the National Medical Products Administration for two drugs, propylthiouracil tablets (50mg) and calcium gluconate sodium chloride injection (50ml:1g/0.3375g), both deemed to have passed consistency evaluation.
Source:
- aastocks.com
- aastocks.com
Jul 10, 2026, 04:08 UTC
Shijiazhuang Yiling Pharmaceutical (02005.HK) announced that 95 of its drug varieties have been included in China's National Essential Drugs List (2026 edition), which will take effect on September 1.
Source:
- aastocks.com
- aastocks.com
Jul 6, 2026, 09:07 UTC
Yiling Pharmaceutical's wholly-owned subsidiary Wan Yang Hengshui Pharmaceutical received approval from the National Medical Products Administration for its irbesartan active pharmaceutical ingredient listing application.
Source:
- finance.sina.cn
- finance.sina.cn
Jul 2, 2026, 00:07 UTC
Shijiazhuang Yiling Pharmaceutical (Shijiazhuang Yiling Pharmaceutical) obtained a drug production registration certificate for Methocarbamol Tablets (0.5g) from the National Medical Products Administration (NMPA), becoming the first domestic company to receive such approval.
Source:
- finance.sina.cn

002603.SZ

China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.

Yiling Pharmaceutical announced its first-half 2026 results with revenue of 4.075 billion yuan, net profit of 757 million yuan, and no dividend distribution.

Yiling Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of its self-developed Class 1 chemical new drug LB220-D08 sustained-release tablets, a complement inhibitor targeting Factor B for atypical hemolytic uremic syndrome.

Shijiazhuang Yiling Pharmaceutical (02005.HK) obtained a drug production registration approval from the National Medical Products Administration for fenofibrate choline sustained-release capsules, classified as Category 4 chemical drugs and deemed to have passed consistency evaluation.

Shijiazhuang Yiling Pharmaceutical (02005.HK) announced that 95 of its drug varieties have been included in China's National Essential Drugs List (2026 edition), which will take effect on September 1.

Yiling Pharmaceutical's wholly-owned subsidiary Wan Yang Hengshui Pharmaceutical received approval from the National Medical Products Administration for its irbesartan active pharmaceutical ingredient listing application.

Shijiazhuang Yiling Pharmaceutical (Shijiazhuang Yiling Pharmaceutical) obtained a drug production registration certificate for Methocarbamol Tablets (0.5g) from the National Medical Products Administration (NMPA), becoming the first domestic company to receive such approval.